AmSurg Reports Net Earnings From Continuing Operations Of $0.51 Per Diluted Share For Second-Quarter 2012

Christopher A. Holden, President and Chief Executive Officer of AmSurg Corp. (NASDAQ: AMSG), today announced financial results for the second quarter ended June 30, 2012. Revenues for the quarter were $231.6 million, a 23% increase from $187.5 million for the second quarter of 2011. Net earnings from continuing operations attributable to AmSurg common shareholders increased to $16.2 million, or $0.51 per diluted share, for the second quarter of 2012 from $12.7 million, or $0.40 per diluted share, for the second quarter of 2011, which included acquisition transaction costs of $0.02 per diluted share. Excluding these costs from the prior year, net earnings from continuing operations per diluted share attributable to AmSurg common shareholders increased 21% to $0.51 for the latest quarter from $0.42 for the second quarter last year.

Revenues for the first six months of 2012 increased 26% to $461.8 million from $365.2 million for the same period in 2011. Net earnings from continuing operations attributable to AmSurg common shareholders increased to $31.9 million, or $1.01 per diluted share, for the first six months of 2012 from $24.3 million, or $0.78 per diluted share, for the first half of 2011, which included acquisition transaction costs of $0.02 per diluted share. Excluding these costs from the prior year, net earnings from continuing operations per diluted share attributable to AmSurg common shareholders increased 26% to $1.01 for the first half of 2012 from $0.80 for the comparable 2011 period.

Mr. Holden remarked, “AmSurg’s second-quarter results represent the third consecutive quarter in which our revenues have grown in excess of 20% on a comparable-quarter basis. For the latest quarter, this growth was driven by a 3% increase in same-center revenue, as well as an expansion in the number of centers in operation to 228 at the quarter’s end from 206 centers at the end of the second quarter last year. Our centers produced a 14% increase in procedures for the latest quarter compared with the second quarter last year, and revenue per procedure increased 8%, consistent with the growth in multi-specialty centers as a percentage of our center mix since the second quarter last year.

If you liked this article you might like

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

'Mad Money' Lightning Round: Kroger, Dunkin' Brands

Jim Cramer's 'Mad Money' Recap: Trump Trade War Could Hit U.S. Car, Apple iPhone Sales

Analysts' Actions -- Tableau, Nucor, Pfizer, Square and More

Mednax Remains Unlikely Target as Medical Mergers Gain Steam